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This study aimed to determine if a dietary intervention of fish oil could reduce the risk of 
metabolic syndrome phenotype associated with glucocorticoids (GC), given as part of the 
acute lymphocytic leukemia (ALL) treatment. Weaned C57BL/6 male mice were 
assigned either a standard rodent chow or Western-type diets containing 45% calories 
from fat consisting of lard (high omega-6/low omega-3 fatty acids). At six weeks of age, 
GC treatment was given daily for 28 days to half the mice in each diet group. Mice on the 
lard diet either remained on this diet or were switched to an isocaloric diet containing 
45% fat from fish oil (high omega-3/low omega-6 fatty acids). Our data showed that the 
fish oil diet (high in omega-3 fatty acids) reduced body mass gain, fatty liver 
development, and glucose tolerance when used in combination with high dose GC 
therapy. The data suggests that consuming more omega-3 fatty acids than omega-6 fatty 
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Pediatric acute lymphoblastic leukemia (ALL) constitutes 30% of all childhood 
malignancies in the United States, making it the most common form of childhood 
cancer.1 This cancer originates with abnormal white blood cell (lymphoblast) 
accumulation in the bone marrow and blood.1,2 The current event-free survival rate is 
now 75%-85% for patients diagnosed with pediatric ALL.2 However, despite a very 
successful cancer treatment, these survivors have multiple long term negative health 
consequences that are associated with an increase in body mass. These detrimental side 
effects resemble metabolic syndrome and comprise of specific symptoms of abdominal 
obesity, impaired glucose tolerance, high blood pressure, elevated triglyceride levels, low 
high-density lipoprotein (HDL) levels, and recently added, non-alcoholic fatty liver 
disease (NAFLD).  
The standard treatment protocol for ALL includes multiple chemotherapeutic 
agents and high dose glucocorticoids. During the induction phase (first 28 days of 
therapy) patients receive Vincristine, Daunorubicin, PEG-Asparaginase, 
Cyclophosphamide, Cytarabine, and Mercaptopurine along with approximately 40 
mg/m2/day of synthetic glucocorticoids, specifically Prednisone.3 
It is well known that chronic glucocorticoid treatment alters metabolic programs 
favoring weight gain.4 During ALL treatment most weight gain occurs during the 
induction phase of treatment during which time high doses of the synthetic 
glucocorticoid, Prednisone/Prednisolone, is administered. This suggests that the treatment 




 Glucocorticoids (GCs) are stress hormones naturally secreted by the adrenal 
cortex to help decrease inflammation and control energy metabolism. As stated above, 
certain GCs such as Prednisone/Prednisolone are part of the chemotherapy treatment 
protocol of pediatric ALL.6 Prednisone/Prednisolone is typically used for its anti-
inflammatory and cytolytic effect on thymocytes and therefore, is essential in treatment 
because of the dramatic increase in immature thymocytes as well as 
chemotherapy-induced inflammation seen during pediatric ALL.7 Synthetic GCs are 
shown to cause massive cell death, or apoptosis, in lymphoid malignant cells by 
transcriptionally regulating and altering a variety of different genes.8 GCs bind to ligand-
activated zinc finger transcription factors called glucocorticoid receptors (GRs) found in 
the cytosol of the cell. After binding to GRs, GCs move to the nucleus and function as a 
DNA sequence-specific transcriptional regulator of certain GC-responsive target genes.9 
These target genes are shown to help control hepatic energy metabolism, especially 
protein and sugar homeostasis.4   
Sugar homeostasis is the balance of insulin and glucagon to maintain steady 
ranges of blood glucose levels. When blood glucose is high, insulin is secreted by the 
pancreatic beta cells to facilitate the transport of glucose into the cells for energy. During 
a fasted state or prolonged exercise, glucagon from the alpha cells of the pancreas and 
natural GCs are released to simulate catabolic reactions in the body by antagonizing 
anabolic insulin actions.4 However, a chronic increase of natural or synthetic GCs can 
alter certain processes causing an increase in anti-inflammatory molecules and 
gluconeogenic enzyme levels such as an increase in phosphoenolpyruvate carboxykinase 




carbohydrate precursors to make glucose, which causes an increase in blood glucose 
levels. Other alterations caused by GCs can lead to the inhibition of glucose uptake into 
muscle and adipose tissue as well as increased adipose tissue lipolysis to generate fatty 
acids as an energy source for muscles. These alterations promote a further rise in blood 
glucose levels and eventually insulin resistance or type 2 Diabetes Mellitus.4 Free Fatty 
acids have been shown to be elevated in obese individuals due to enlarged adipose tissue 
that releases more free fatty acids. Free fatty acids can cause an increase in blood glucose 
by inhibiting insulin’s anti-lipolytic action, leading to an increase in the rate of free fatty 
acids into circulation. 10 Furthermore, an increase in free fatty acids can increase the 
secretion of glucagon, and therefore, gluconeogenesis and high levels of glucose in the 
blood. 11 
Although acute exposure of GCs increases lipolysis in adipose tissue, chronic use 
of GCs can lead to an increase in total mass of adipose tissue, especially in conjunction 
with a high fat diet (HFD) that is low in omega-3 polyunsaturated fatty acids (n-3).12,13 
Increases in adipose tissue may be caused by the redistribution of fat from peripheral to 
central and visceral depots leading to further deregulation of the metabolism. Most 
pediatric patients with ALL, as well as patients with Cushing’s syndrome, have fat 
redistribution as a common phenotype. The shared feature between these two types of 
patients is chronically increased GCs of either natural or synthetic origins, with the 
naturally increased GC levels occurring due to irregular hormonal and metabolic 
processes and stress responses.4,14  
Changes in fat distribution are not the only issues with chronic exposure to GCs. 




promote other inflammatory issues that stimulates steatosis of the liver.15 Chronically 
elevated GC levels alter the regulation of liver processes which can cause increased 
triglyceride synthesis, decreased fatty acid oxidation, and increased accumulation of 
lipids, leading to fatty liver.16   
Long-term deregulation of hepatic processes is detrimental as the liver is 
responsible for the control of glucose and lipid homeostasis. Untreated liver disease can 
result in liver failure and even death.17 Non-alcoholic fatty liver disease (NAFLD) is a 
chronic inflammatory condition that can range from simple steatosis, also called simple 
fatty liver, to nonalcoholic steatohepatitis (NASH). NASH can later progress into more 
advanced inflammatory stages such as fibrosis, cirrhosis, hepatic apoptosis, and 
hepatocellular carcinoma.18 Fatty liver results from the accumulation of triglycerides in 
the cells due to an increased uptake of free fatty acids and de novo liponeogenesis in the 
hepatocytes while also exhibiting a decreased secretion of very low density lipoprotein 
cholesterol (VLDL-C) out of the liver.19 GCs alter the transcriptional regulation of many 
different metabolic genes and enzymes such as glucose-6-phosphatase (G6Pase) and 
PEPCK. These alterations have an immense effect on how macronutrients are 
metabolized and stored in the body. However, the entire effect of GC treatment in 
concurrence with a HFD on hepatic inflammation and fibrosis remains unclear. There is 
some evidence that a HFD of about 60% of calories in conjunction with GCs rapidly 
induces the development of fatty liver disease. In addition to the production of fatty liver 
disease, there is lipid spillover from central adipose tissue, which rapidly promotes 




Conversely, studies have found positive effects of a HFD that is high in n-3 fatty 
acids on improved liver outcomes such as a decrease in hepatic steatosis, inflammation 
and necrosis.20 Omega-3 fatty acids have been shown to be safe and effective for the 
treatment of fatty liver disease by improving hypertriglyceridemia and down regulating 
leptin and resistin levels and upregulating adiponectin expression.20,21  In turn, increased 
adiponectin levels are associated with decreased liver inflammation and fibrosis as well 
as decreased hepatic and systematic insulin resistance.22 
Insulin resistance, also known as Type 2 Diabetes Mellitus, can be a consequence 
of chronic liver disease, especially in the presence of hyperlipidemia. Insulin lowers 
blood glucose and inhibits lipolysis. Therefore, hyperlipidemia in combination with 
insulin resistance favors an increase in fat mass and lipolysis, causing elevated levels of 
free fatty acids and therefore, a further decrease in the effectiveness of insulin signals. 
The reduced insulin signaling causes hyperglycemia, which leads to elevated hepatic 
glucose, up regulation of de novo liponeogenesis, and a further increase in free fatty 
acids.23 The rise of free fatty acids causes an escalation of oxidative stress, fatty liver 
disease, and increase in adipose tissue. Insulin resistance and the accumulation of 
adipokines, such as leptin and the pro-inflammatory cytokines, Tumor Necrosis Factor 
alpha (TNF-α) and interleukin 6 (IL-6), exacerbate the oxidative stress and perpetuate the 
liver inflammation leading to further liver damage.24 
TNF-α is released by adipose tissue associated macrophages (ATMs).25 Previous 
work demonstrated that an increase in GCs causes adipocyte hypertrophy and thereby 
increases pro-inflammatory TNF-α secretion.26 TNF-α is an inhibitor of the GLUT4 




thus causing a prevention of glucose uptake in the cells.25 Therefore, GCs may cause 
insulin resistance as a result of the increased release of TNF-α from hypertrophied 
adipocytes. This accounts for increased TNF-α serum levels that are present during 
obesity and hyperinsulinemia.27   
Another component of weight management is the hormone leptin. This hormone 
is responsible for the regulation of energy balance through the suppression of appetite in 
order to reduce food intake. 28 Increased leptin, along with decreased adiponectin, has 
been shown to be connected with amplified severity of steatosis and fibrosis of the liver 
and increased occurrence of insulin resistance.29 Previous animal studies have shown that 
n-3 treatment can cause a decrease in leptin and resistin levels in serum and adipose 
tissue, while increasing the adipokine, adiponectin, over time.20 Adiponectin expression 
can be inhibited by both GCs and the pro-inflammatory cytokine TNF-α.26 Excess TNF-α 
and leptin hormone has also been shown to impair insulin resistance by inducing insulin 
resistance in pancreatic β cells by stimulating the release of mediators that are toxic for 
these cells.30,31  
These factors that cause insulin resistance and NAFLD can cause patients to 
experiences signs and symptoms of NAFLD such as malaise, fatigue, right upper 
quadrant pain, abdominal discomfort, hepatomegaly, jaundice, ascites, and indications of 
metabolic syndrome. However, most cases of NAFLD can appear as asymptomatic, and 
therefore, biomarkers are useful to assess liver status including aspartate- and alanine 





While the liver and the pancreas are key regulatory organs of metabolism, other 
important and less studied organs are the small and large intestines. Former studies have 
shown that GCs may play a role in the increased intestinal uptake of glucose, which may 
contribute to the development of hyperglycemia in patients on chronic GC therapy.32 
There are a variety of sugar transporters in the intestine including GLUT2, GLUT5, 
GLUT7, GLUT9, and sodium-dependent glucose co-transporter (SGLT1).33 The variety 
is indicative of adaptation of the intestinal sugar transport system depending on the 
different dietary proportions of macronutrients consumed.34 Although there is limited 
evidence on how these transporters function during digestion, carbohydrates in the 
intestine require absorption by a two-step, two-membrane-transport process. The SGLT1 
and the facilitative fructose transporter, GLUT5,	in the brush border membrane lining the 
intestinal lumen35 absorb monosaccharides, GLUT2 is a facilitative transporter of both 
glucose and fructose in the basolateral membrane of the small intestine and is activated 
by glucose transport through SGLT1.36, 37  
 During postnatal small intestinal development specific GCs have been shown to 
regulate cytokine gene expression. This suggests that cytokines may alter sugar 
absorption.38 Some studies have shown also that Prednisone increased glucose absorption 
while other studies resulted in no effect.39 An increase in glucose being transported to the 
liver could lead to increased fat accumulation in the liver, which can be another 
determinant of NAFLD.  
Limited, but current research shows that the ratio of omega-6 fatty acids (n-6) to 




phenotypes such as obesity, NAFLD, dyslipidemia, and insulin resistance observed in 
these pediatric patients.40–43 
Omega-3 fatty acids play a beneficial function in the reduction of pro-
inflammatory cytokines such as TNF-α and IL-8, reducing the risk of liver disease and 
insulin resistance.44 Omega-3 fatty acids may increase anti-inflammatory cytokines by 
incorporating n-3 fatty acids into cell membrane phospholipids, which interferes with the 
metabolism of linoleic acid (LA), the n-6 precursor to arachidonic acid (AA). Omega-3 
and n-6 fatty acids are competitively metabolized by the same enzyme system, therefore, 
the PUFA that is most abundant will be preferentially metabolized. When n-3 fatty acids 
are most abundant, they will replace AA in the cell membrane and decrease the pro-
inflammatory derivatives of AA. If more n-6 fatty acids are present, then the pro-
inflammatory AA-derived eicosanoids will dominate over the anti-inflammatory n-3 
derived eicosanoids. 45 When having a higher dietary intake of n-3 fatty acids, there is an 
increase in anti-inflammatory mediators and a decrease in the pro-inflammatory 
mediators, which will reduced inflammation and oxidative stress.46  
Although considerable research has been devoted to proving the beneficial effects 
of GCs as part of the treatment therapy for ALL, few studies have addressed the role of 
nutrition, specifically fatty acids, in the reduction of detrimental side effects caused by 
chronic GC use.  
Certain PUFAs have been advertised as a beneficial component in the diet that 
may aid in the reduction of inflammation as well as the decrease in the prevalence of 
atherosclerosis, obesity, and diabetes.20 The two major types of essential PUFAs that 




are commonly found in the forms of essential α-linolenic acid (ALA), eicosapentaenoic 
acid (EPA), and docasahexaenoic acid (DHA) and are found in food sources such as fish, 
flaxseed oil, and seeds.48,49 These specific forms have been shown to decrease 
inflammation by reducing the eicosanoids and other mediators derived from AA.50 
Eicosanoid products such as prostaglandins are derived from n-6 fatty acids. Therefore, 
the appropriate ratio between n-6 and n-3 fatty acids is critical to produce positive health 
effects.51 Common types of dietary n-6 fatty acids are LA and AA, which are found in 
nutritional sources such as liquid corn, sunflower, olive, and safflower oils. The western-
type diet characteristically contains low PUFAs with a higher amount of n-6 fatty acids 
than n-3 fatty acids. This high ratio of n-6 fatty acids:n-3 fatty acids leads to an increase 
in inflammation and issues regarding weight and metabolism.52  
Obesity and metabolic disorders have increased over the past decade due to the 
increased consumption of a western-type diet, which is high in calories, saturated fat, and 
sugar and low in n-3 fatty acids.  Pediatric patients undergoing treatment for ALL often 
consume foods high in saturated fat, n-6 fatty acids, and sugar before, during, and after 
treatment. Increased consumption of these types of foods contributes to the increase in 
visceral adipose tissue, NAFLD, insulin resistance, and glucose transporter deregulation, 
which are also phenotypes that ALL patients develop.15 However, increasing 
consumption of n-3 fatty acids may be able to decrease GC induced health consequences 
including the redistribution and increase of adipose tissue, as well as the increase in the 
occurrence of inflammation, hypertension, hyperlipidemia, and liver disease.12,53  
This information has led to the hypothesis that a western type diet containing high 




syndrome induced by GC treatment. A secondary hypothesis is that the replacement of 
lard (higher in n-6 fatty acids) with fish-derived fat (higher in n-3 fatty acids) will reduce 
the metabolic disorder phenotypes induced by chronic, long-term exposure to GC and 
ultimately reduce the risk for the development of obesity, type 2 diabetes, hypertension, 









Newly weaned C57BL/6 male mice were obtained from breeder pairs (purchased 
from Harlan Laboratories, Inc., Indianapolis, IN) and housed in a USDA approved animal 
facility at the University of Memphis. Mice were weaned to a standard rodent chow diet 
(Chow) (6% kcal from fat) or a Western-type diet containing 45% of the calories from fat 
(HFL n-6) (45 kcal% fat containing predominantly lard, 41% carbohydrate, 20% sucrose, 
9% corn starch, and 12% Maltodextrin 10; Research Diets, Inc., New Brunswick, NJ). At 
six weeks of age, mice were separated into individual cages. Mice on the chow diet 
remained on the diet, while mice on the HFL diet were randomly divided with half 
remaining on the original HFL n-6 and the remainder switched to a diet containing 45% 
kcal fat from Menhaden (fish) oil (HFO n-3) for an additional four weeks (Table 1A) 
(Research Diets, Inc.). All animals received food and water ad libitum and were 
maintained in individual cages with a 12-hour dark/12-hour light cycle. The HFL n-6 and 
HFO n-3 diets both contained 45% of kcals from fat. The HFL n-6 diet contains a greater 




contains a greater amount of Stearic, Oleic, and Linoleic fatty acids than the HFO n-3 
diet. The HFO n-3 diet contains a greater composition of Myristic, Palmitoleic, 
Stearidonic, Eicosapentaenoic (EPA), Docosapentaenoic, and Docosagexaenoic (DHA), 
which are the n-3 fatty acids that have been shown to be beneficial in decreasing 
inflammation in the body and decrease the risk of cardiovascular and other metabolic 
issues.59 Due to the increase in the n-3 fatty acid components compared to the n-6 fatty 
acid components in the HFO n-3 diet, the n-6 to n-3 fatty acid ratio is lower in the HFO 
n-3 diet. (Tables 1 A and B).  
Mice further received daily doses of the GC Prednisolone or vehicle only for the 
final four weeks. Prednisolone was administered at 0.003 grams/mouse/day (40 
mg/m2/day) in a vehicle of 0.25g sweet potato. Control mice received 0.25g sweet potato 
only. The prednisolone dose given is based on the amount given to pediatric ALL 
patients during the induction phase of their therapy. Food intake and body mass were 
determined twice weekly. All experiments were conducted in accordance with the 
National Institutes of Health Guidelines for the Care and Use of Experimental animals 




Table 1. Composition of Experimental Diets. HFL n-6 with 45% kcals/g from lard; 
HFO n-3 with 45% kcals/g from menhaden oil. (A) ingredients in HFL-n-6 and HFO n-3 
diets; (B) fatty acid composition of HFL n-6 and HFO n-3 diets.  
(A) 
Ingredients HFL n-6 HFO n-3 
 gm (%) kcal (%) gm (%) kcal (%) 
Casein, 80 Mesh 200 800 200 800 
L-Cystine 3 12 3 12 





Ingredients HFL n-6 HFO n-3 
 gm (%) kcal (%) gm (%) kcal (%) 
Corn Starch 72.8 291 72.8 291 
Maltodextrin 10 100.0 400 100.0 400 
Cellulose, BW200 50 0 50 0 
Soybean Oil 25 225 25 225 
Lard 177.5 1598 0 0 
Menhaden Oil (200 ppm tBHQ) 0 0 177.5 1598 
tBHQ 0.0355 0 0 0 
Mineral Mix S10026 10 0 10 0 
Vitamin Mix V10001 10 40 10 40 
Choline Bitartrate 2 0 2 0 
Cholesterol 0.58 0 0 0 
*BHQ: tertbutylhydroquinone 
(B) 
Ingredients (g) HFL n-6 HFO n-3 
Lard 177.5 0 
Menhaden Oil, ARBP-F 0 177.5 
Soybean Oil 25 25 
Total 202.5 202.5 
C14, Myristic 2.1 14.0 
C16:1, Palmitoleic 2.5 17.7 
C18, Stearic 19.8 6.6 
C18:2, Linoleic 56.2 16.1 
C18:3, Linolenic, n3 4.2 4.3 
C18:4, Stearidonic, n3 0 6.0 
C20, Arachidic 0.4 0.3 
C20:4, Arachidonic, n6 0.5 0 
C20:4, n3 0 3.1 
C22:5, Docosapentaenoic, n3 0.2 4.1 
C22:5, n6 0 0.6 
C22:6, Docosahexaenoic, n3 0 29.0 
Total 190.7 189.6 
Saturated (g) 60.2 59.8 
Saturated (%) 31.6 31.5 
Monounsaturated (g) 67.7 41.3 
Monounsaturated (%) 35.5 21.8 
Polyunsaturated (g) 62.8 88.5 
Polyunsaturated (%) 32.9 46.7 
n6 (g) 57.0 17.9 
n3 (g) 4.4 66.6 





Small intestines were harvested and length measured. Liver and epididymal 
adipose tissues were harvested and weighed. A portion of each tissue was fixed in 
formalin (Fisher Scientific Co. LLC) embedded in paraffin and 4um sections were 
stained with hemotoxylin and eosin. The mean adipocyte area (average surface area of 
10-15 randomly selected adipocytes from each mouse (n=6) were determined using 
Axiovision r4.8.2 software. Analysis and documentation were performed using an imager 
M2 microscope (Axiocam MRC, Zeiss).  
Glucose Uptake  
Glucose uptake was measured in vitro using the everted sleeve method.60 Briefly, 
small intestines were harvested and immediately transferred into cold mammalian 290 
mOsm Ringer solution (117 mmol NaCl, 4.7 mmol KCl, 1.2 mmol KH2PO4, 1.2 mmol 
MgSO4 and 20 mmol NaHCO3). 1.5 cm long segments were cut starting at the most 
proximal region of the intestine. The 1.5 cm segments were everted and secured onto the 
ends of a four mm-diameter stainless steel rods using surgical thread to secure the ends. 
Mounted tissues were immediately placed in ice-cold 290 mOsm aerated (95% oxygen 
and 5% CO2) Ringer solution. Mounted tissue samples were incubated for five minutes in 
37°C aerated Ringers solution before being positioned for two minutes over a stir bar 
rotating at ~1,200 rpm in a solution of aerated mammalian Ringers solution containing 50 
mmol/L D-glucose and a tracer concentration of radiolabeled (14C) D-glucose to 
determine D-glucose uptake by the tissues.  Radiolabelled (3H) L-glucose was added to 
the incubation solution to correct for D-glucose that is associated with the adherent fluid 




in cold mammalian ringers solution, removed from the rods, and weight was determined.  
The tissues were solubilized (Solvable, Perkin Elmer, Waltham, MA) at 55°C for four 
hours, scintillation fluid was added (Ultima Gold, Perkin Elmer, Waltham, MA), and 
disintegrations per minute were measured. (Tri-Carb 2900TR, Perkin Elmer, Waltham, 
MA). Calculated rates of glucose absorption were expressed as nmoles of D-glucose 
transported per minute per mg of tissue. 
Metabolic Parameters  
Metabolic parameters were determined on days 14 and day 27 after the diet 
switch and start of Prednisolone treatment.  Fasting blood glucose levels were measured 
after mice were fasted for six hours. Glucose was administered at a concentration of 
1g/kg of animal weight via an intraperitoneal injection. Blood samples from the tail vein 
were collected every 30 minutes for a 90 minutes period. Blood glucose was determined 
using a glucose meter (Onetouch Ultra 2 Meter). 
Lymphoid Parameters   
To determine Prednisolone efficacy, spleens were harvested and weighed. 
Splenocytes were isolated and counted using a hemacytometer and trypan blue was used 
for dead cell exclusion. 
Liver Enzymes  
Liver enzymes were measured using an Alanine Transaminase (ALT) Activity 
Assay kit (Abcam ab105134). Activity was determined according to manufacturer’s 
instructions. Samples were diluted 1:5 in the assay buffer and colorimetric change was 
determined after 60-minute incubation and reading at 570nm using a microplate reader 




Statistical Analyses  
Statistical significance was determined using the Mann-Whitney U test and. p < 







Diet Containing Fat From Menhaden Oil Reduced Body Mass Gain and 
Adiposity Independent of Glucocorticoid Treatment. Mice given a diet containing 
45% fat from fish oil (Menhaden oil; major fatty acids EPA and DHA) had reduced body 
mass gain over a 28 day period as compared to mice fed an isocaloric diet containing 
45% fat from lard, resulting in a significantly reduced body mass at the end of the 
experimental period (Figures 1 and 2). The glucocorticoid treatment (Prednisolone) did 
not significantly increase body mass gain, regardless of diet treatment.  
Mice consuming the diet containing lard averaged an 18% increase in food 
consumed in the presence of the glucocorticoids compared to the fish oil diet  (Figure 3). 
Weight gained per gram of food consumed demonstrated that mice on a fish oil diet gain 
30% less weight (without glucocorticoids) and 32% less weight (with glucocorticoids) 















Figure 1. Weight Gain. Weight (grams) was measured weekly over the 28 day period 
that the mice received GCs while on a Chow, HFL n-6, and HFO n-3 diet (n= 5-6 mice 
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Figure 2. Total Weight Gain. Total weight gained was determined at the end of 28 days 
for each group. Total weight gained did not differ significantly between the Chow and the 
HFO n-3 diet, but there is a significant increase in total weight gain between the HFL n-6 
diet and the HFO n-3 diet (P=0.01 in the absence of GC and P=0.03, in the presence GC) 
























































Figure 3. Total Food Consumption. Total food consumption was determined by 
weekly. In the presence of GC there is not a significant difference in food consumption, 
but the consumption of HFL n-6 diet did lead to a significant difference. (P=0.05, n=7-9 

























































Figure 4. Weight Gained per Gram. GC treatment did not increase the weight gained 
per volume of food. There is a significant difference in the amount of weight gained per 
volume of food consumed (p=0.02, n=7-9 mice per group) of food consumed in mice on 




Glucocorticoid Treatment Reduces Spleen Size Independent of Diet. 
Glucocorticoids have become part of the standard treatment for childhood ALL due to its 
cytolytic effects on thymocytes. Concomitantly with this decrease in immune cells is a 
reduction in immune organs size, including spleens.7 To confirm GC efficacy spleen 
weight and spleenocyte number were determined. There was a reduction is spleen size 
compared to normal spleen sizes for the chow diet (22% reduction), lard diet (24% 























































number (Figure 6). Interestingly there was a significant difference in spleen sizes with the 
fish oil diet as compared to the chow or lard diet, where the HFO n-3 diets demonstrated 





Figure 5. Spleen Weight. Spleens were harvested and weight determined. There was no 
significant difference between groups, but the spleen exposed always tended to be 
















































Figure 6. Splenocyte Numbers. Spleens were harvested and splenocytes isolated and 
counted using a hemacytometer and Trypan Blue exclusion dye. The P value for Chow 




No Difference In Intestinal Glucose Uptake was Observed.  
One successful experiment using the sleeve method to measure intestinal glucose 
absorption showed no difference in intestinal glucose uptake between mice on lard and 
fish oil diet (Data not shown). However, the small intestine lengths of mice fed the HFL 






Figure 7. Small Intestine Lengths. Lengths measured in cm of mice on chow, HFL n-6, 




Liver and histology 
Figure 8A demonstrates a significant decrease in liver weight with glucocorticoid 
treatment when the animals were on a standard chow diet (P = 0.05). No differences 
were observed in liver weight between untreated chow diet and the two high fat diets. 
Despite the fact that mice on the high fat diets have similar liver weight independent of 






























the lard diet by histologic examination. (Hematoxylin-eosin staining; Figure 8B) This fat 




















































Figure 8.  Liver Weight Morphology and Histology. (A) Livers were harvested and 
weighed; there was no increase in liver weight with the high fat diets, but GCs caused a 
decrease in liver weight when on a Chow diet. (B) Histology revealed an increase in fatty 
deposits in the liver (fatty deposit indicated by arrow) when on a HFL n-6 diet, but it is 


















Plasma Analysis of Liver Parameters was Not Significant.  
Plasma Alanine Aminotransferase (ALT) activity was higher in the GC groups for 
both the HFL n-6 and HFO n-3 diets. However, the differences in plasma ALT activity 
were not significant when comparing the six groups (Figure 9).  
 
 
Figure 9. Liver Enzyme Activity. Plasma ALT activity levels were determined and 


















































Adipose Tissue Characteristics and Histology Were Observed for Differences in 
Weight and Size.  
 The weight of the epididymal fat pads reflected the overall weight of the mouse 
with the lard diet causing a significant increase in fat deposition as compared to the fish 
oil diet (P = 0.01 without glucocorticoid treatment and P < 0.0001 with glucocorticoids 
treatment; Figure 10A). As with body mass, glucocorticoids did not increase adipose 
tissue weight. However, histologically, there was a significant increase in adipocyte size 




























Figure 10. Adipose Tissue Weight and Morphology. (A) Epidydimal fat pads were 
harvested and weighed. Mice on HFL n-6 had significantly larger fat pads, independent 
of GC treatment (p=0.0001). (B) Adipocyte morphology (20X magnification) 
demonstrate that the HFL diet increased the adipocyte size as compared to the Chow and 
HFO diet and that GCs exacerbate this phenotype significantly when on the HFL diet 
(p=0.0001).  
 
Plasma Blood Glucose Levels Were Higher in HFL n-6 Diet Mice than HFO n-3 Diet 
Mice. 
The impact of 40 mg/m2/day of GC administration on glucose tolerance in 
correlation with the two different HFDs was assessed with an intraperitoneal glucose 
tolerance test (GTT). Our results show that a HFL n-6 diet caused a greater increase in 
blood glucose levels compared to the mice on a HFO n-3 diet. (Figure 11 A and B).  The 
blood glucose levels of the HFL n-6 group with GC administration appeared to be higher 






compared to the HFL n-6 groups without GCs. Figure 11 A and B demonstrates that the 
HFO n-3 diets showed similar blood glucose uptake throughout the course of the GTT 
regardless of the presence or absence of a GC. Glucose uptake of the HFO n-3 diet group 
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Figure 11. Glucose Tolerance test. (A) Blood glucose concentration (mg/dl) was 
measured over 90 minutes.  (B) At 90 minute after glucose (1g/kg) administration, 
glucose levels were increases with the HFL n-6 diet and trended trend towards glucose 

























































Patients undergoing ALL treatment (which includes high dose GCs) have an 
increased risk of developing metabolic syndrome later in life.14,61,62 Pediatric survivors 
typically demonstrate signs of obesity, insulin resistance, dyslipidemia, and hypertension 
in remission from ALL indicating that GCs may have long term side effects even after 
therapy.14,62 These side effects may be due to GCs main role in decreasing inflammation 
by suppressing the immune system and controlling energy metabolism, especially hepatic 
energy metabolism.   
GCs have a role in ALL treatment due to their anti-inflammatory and cytolytic 
effects.8 As GCs reduce immune cells, there is a concomitant reduction in the mass of 
immune organs. The significant decrease in spleen weights and spleen cells confirmed 
that GCs had a similar effect on immune cells and associated organs during the 28-day 
treatment.  
Due to the unquestionable evidence of dietary intervention on human health, we 
focused our efforts on the effects of a diet high in n-6 fatty acids from lard compared to a 
diet high in n-3 fatty acids from fish oil. Our results mirrored data	from a previous study 
reporting that animals consuming a diet high in n-3 fatty acids had less total adipose 
tissue, intra-abdominal fat, and less insulin resistance than a animals consuming a high 
fat lard diet. 63 The mice in the present study showed that the HFL n-6 diet promoted 
more overall weight gain, adipose tissue gain, more food consumption, and more weight 
gain per gram food than the mice on the HFO n-3 diet. This is in accordance with 




oxidation suggesting that the n-3 fatty acids may be protective against adipose tissue 
gain. It is now well established that n-3 fatty acids in fish oil increases fatty oxidation 
while the n-6 fatty acids from lard induces the expression of transcription factors that 
regulate lipid homeostasis such as Sterol Regulatory Element Binding Protein (SREBP), 
which promotes fatty acid synthesis.64 The result of the weight gained by the mice 
demonstrates that the type of diet has a greater effect on weight gain than the presence of 
GCs.  
Histological evaluation of the epididymal fat showed that the adipocytes from the 
HFL n-6 diet were larger in diameter compared to both the HFO n-3 and Chow diets. The 
adipocytes on the chow and HFO n-3 diet were similar in size, indicating that the n-6 
fatty acids in the lard diet may alter physiological mechanisms that increase the size of 
the adipocytes. Moreover, the administration of glucocorticoids caused a significant 
increase in adipocyte size, but only when mice were exposed to the n-6 lard diet.   
Long-term use of GCs can cause NAFLD due to alterations in hepatic 
metabolism.4 NAFLD results from a combination of insulin resistance and an increase in 
the uptake of free fatty acids and de novo liponeogeneisis in the hepatocytes leading to an 
accumulation of stored fat in the liver.4 Although there were no histological differences in 
fatty deposition in the liver between the HFL n-6 with and without GCs, ALT enzymes 
were increased in the HFD groups with GCs, albeit not significantly. This may indicate 
that the GCs could be causing liver damage, however, liver damage indicated by elevated 
plasma ALT levels and fibrosis, typically does not develop with less than four weeks of 
high fat feeding.65–67 A longer time on the HFD may be needed to see more true liver 




show that the HFL n-6 diet caused more fat accumulation than the chow or HFO n-3 
diets, which could further develop into more liver damage with a longer study period on 
the HFD indicated by high ALT enzyme levels and liver fibrosis. Therefore, the HFO n-3 
diet may be protective and decrease the risk of NAFLD.  
Similar to other findings where hyperglycemia was seen in a HFD in conjunction 
with a GCs, the data from the GTT’s throughout our study demonstrates that the HFL n-6 
diet rapidly induced a type 2 diabetic phenotype after four weeks on the diet.15 This was 
characterized by glucose intolerance as measured by an intraperitoneal glucose tolerance 
test over 90 minutes. Due to the research that shows that insulin resistance could lead to 
NAFLD, a longer study period could show more data that demonstrates the development 
of NAFLD68. 
Fatty acids in the liver can alter glucose metabolism, therefore we evaluated 
possible alterations in intestinal uptake of glucose by the inverted sleeve method to 
determine if there is an alteration in glucose uptake in the presence of the different fatty 
acid composition in the diet. 69 Due to controversial research regarding the fluctuation of 
glucose transporters in the small intestines, we measured rates of glucose uptake by the 
small intestines of mice fed the HFL n-6 diet and the HFO n-3 diet. The data suggested 
that glucose uptake of the small intestine is not affected by the type of diet consumed 
during the seven weeks on the diet. However, there was a significant decrease in 
intestinal length of mice consuming the HFL n-6 diet as compared to the mice consuming 
a chow and HFO n-3 diet. However, the small intestines in both HFD groups showed to 
have similar glucose absorption rates, indicating that the number of transporters was most 




intestinal lengths could possibly indicate that chow and HFO n-3 diet mice could have 
more glucose uptake capacity than the HFL n-6 diet mice. Further understanding of why 
a diet high in n-6 fatty acids could cause a decrease in intestinal size and yet, still advance 








This study demonstrates that a high fat diet higher in n-6 fatty acids can lead to 
detrimental side effects, especially in combination with GC therapy. Here we show that a 
diet high in n-6 fatty acids increases total body and adipose tissue weight, per volume of 
food consumed. In addition, the data shows that a HFL n-6 diet in the presence of 40 
mg/m2/day prednisolone increases fatty liver development and insulin resistance. 
However, the replacement of a HFL n-6 diet with a HFO n-3 diet will reduce the 
metabolic disorder phenotypes, specifically hyperglycemia, obesity, and liver disease to 
similar phenotypes of animals consuming a chow diet during glucocorticoid treatment.  
The results suggests that a diet high in n-6 fatty acids may be beneficial for 
pediatric ALL patients undergoing GC treatment and might decrease the risk of 
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A. IACUC Approval 
IACUC PROTOCOL  
FOR USE OF LIVE VERTEBRATES FOR RESEARCH, TEACHING OR DEMONSTRATION 
UNIVERSITY OF MEMPHIS 
 
IACUC Protocol #                                               Date Submitted to IACUC  
 
Dates Protocol will be in effect:                              from                                  to  
(not to exceed three years including two yearly renewals) 
 
Is this protocol related to an external grant or contract application?  Yes          No  X 
If yes, complete the following: 
 




University account for Animal Care Facility per diem charge:   
 
If the protocol is not related to an external grant or contract application, complete 
the following: 
 















Project Title: (If project relates to a grant or contract application, give that title; if the 









Academic Rank:  
 
Campus phone:                                                     Emergency phone:   
 
Attending Veterinarian:    
 
Phone:                                                                   Emergency phone:  
 
List all individuals that will handle animals using this protocol and their level of 
expertise (e.g. relevant qualifications). If the protocol applies to a class then so specify. 
Effect of a dietary intervention on glucocorticoid-induced metabolic syndrome. 
Marie van der Merwe 
Health and Sport Sciences 
 Assistant Professor 
Karyl Buddington 
901 678 3476 901 406 7458 





If additional personnel become involved in handling animals used in this protocol, 
it is the responsibility of the principal investigator to notify the Animal Care 
Facility in writing before they start. 
If applicable, has the investigator/instructor and all personnel listed above  
received the appropriate vaccinations (tetanus, rabies)?                  Yes         No   
Is it necessary for personnel listed on this protocol to be tested for TB? Yes        No X  
If you have questions about the kind of vaccination or about TB, call the Animal 
Care Facility at 678 2034. 
All U of M personnel involved in this protocol must complete the animal care and 
use training program (satisfactory completion of, or concurrent registration in Biol 
7006/8006), or have completed a comparable training program at another 
institution before animals can be procured or before the experiments/teaching or 
demonstration.   In submitting this protocol, I, as Principal Investigator/Instructor 
accept the responsibility for compliance with this requirement. 
In addition, the Principal Investigator/Instructor must be willing to provide 
appropriate supervision for all persons working on this protocol.  In the case of a 
class, the Instructor must be responsible for training any students in classes 
involved prior to using animals. 
II.  Project Description 
A. Summary (Enter a brief description below of your project, using lay 
terminology): 
Marie van der Merwe – PhD (Molecular Pharmacoly), Postdoctoral Fellowship (Bone 
Marrow Transplantation): More than 10 years of experience using mice as a research 
model. 
 
Simone Godwin – BA (Anthropology), Animal husbandry internship at Duke Lemur Center 
(Durham), Primate conservation and rehabilitation internship at Alouatta Sanctuary 
(Panama) 
 









B. Describe IN DETAIL the procedures you will follow. You may do this in either of 
two 
 ways (Check one of the options below and follow the associated instructions): 
1. Accompanying documentation (include documentation in box below).                       
X   OR 
2. By reference to previously published work (provide a complete bibliographic 
citation in the box below, and describe any variations from the published 
technique).     
Acute lymphoblastic leukemia (ALL) treatment increases the risk for pediatric patients to 
develop obesity and symptoms similar to metabolic syndrome including type-2 diabetes and 
dyslipidemia. The treatment includes many chemotherapies and also high doses of 
glucocorticoids. The long term use of glucocorticoids has been associated with the 
increases in weight and also symptoms similar to metabolic syndrome. The goal of this 
experiment is to determine if dietary interventions can reduce risk and long term 
consequences associated with the use of glucocorticoids.  
 
We will use a mouse model (C57BL/6) that will receive a 45% fat (lard) diet, similar to a 
Western diet. Control mice will be on a “normal” 10% fat diet. As an intervention, the fat 
source will be altered to a 45% fish oil diet (omega-3 fatty acids). Omega-3 fatty acids have 
been shown to reduce inflammation and decrease risk of development of glucose 
intolerance. While on the various diets, mice will be given the glucocorticoid, prednisone at 
a dose of 40mg/m2/day for 28 days. Prednisone will be administered orally using a vehicle 
on a daily basis. 28 days reflect the induction phase of ALL treatment during which time 
the patients receive high doses of prednisone and experience a dramatic increase in weight.  
 
Eating habits (amount of food consumed) and weights of mice will be monitored twice a 
week. After two weeks (14 days), half of each group of mice will be anaesthetized to 
perform a DEXA scan (whole body fat composition) Blood will be drawn to determine 
glucose and insulin levels. A glucose tolerance test will be performed by administering 
glucose and then measure glucose levels in blood at various time points. The mice will be 
sacrificed to harvest brain, adrenal glands, liver, spleen, mesenteric lymph nodes and 
adipose tissue for analysis. The remainder of the mice will go through the same process at 





Mice: C57BL/6 male mice will be used for this study and obtained from breeder pairs that are bred and 
housed at the animal facility on the University of Memphis campus.  
Diets and treatments:  All of the mice will be weaned at 3 weeks of age to the western diet with 45% 
lard and 41% carbohydrate (20% sucrose, 9% corn starch and 12% Maltodextrin 10). For Specific Aim 
1 the mice will remain on this diet.  For Specific Aim 2 the lard component will be replaced using fish 
oil at the start of glucocorticoid treatment to provide the long chain omega-3 fatty acids.  The diets will 
be purchased from Research Diets, which has experience in producing the western diet for rodent 
studies. 
Glucocorticoid therapy:  To resemble the age group of ALL patients treated at St Jude, mice will be 6 
weeks of age at the start of glucocorticoid therapy. Mice of this age are comparable to a 4 year old 
child.  The glucocorticoid treatment will last for 28 days.   Prednisone (40 mg/m2/day) will be orally 
administered on a daily basis by adding it to a vehicle of canned sweet potato or other canned fruits or 
vegetables. If the vehicle is not sufficient to mask the taste of prednisone, we might use prednisolone 
that is bioequivalent to prednisone, but is more palatable. This might only be needed for the first 
couple of doses as the increase of appetite drivel by the glucocorticoid might drive the consumption of 
the drug in vehicle. If prednisolone is not efficiently consumed, we will administer the drug by gavage. 
Again, this might only be required for the first couple of days until their appetite increases.  
Experimental design: 
For Specific Aim 1, 40 male mice will be divided into 2 experimental groups, with all mice fed the 
western diet with lard and with or without the addition of the glucocorticoid (GC) treatment 
(20/group).  Half of each group - 10 mice – will only be treated for 14 days.  This group will be 
anaesthetized (isoflurane) after a 10 h fast, a DEXA scan performed (anesthetized for 15 min) and 
blood collected via the saphenous vein in one of the back legs to determine fasting glucose and insulin 
levels and also determine cytokine levels. For the glucose tolerance test, these mice will be given a 1g 
glucose/kg body weight intraperitoneally and blood collected every 30 minutes for 90 minutes to 
measure glucose levels. Mice will then be euthanized (CO2 inhalation) to collect brain, adrenal glands, 
liver, spleen, mesenteric lymph nodes and adipose tissue for histology, biochemistry and immune cells 
harvest. This data will reveal if there is any early indication of the metabolic phenotype. The remainder 
of the mice will remain on the glucocorticoid treatment for another 14 days at which point this group 
will be anaesthetized (isoflurane) after a 10 h fast, a DEXA scan performed and blood collected via the 
saphenous vein in one of the back legs to determine fasting glucose and insulin levels and also 
determine cytokine levels. For the glucose tolerance test, these mice will be given a 1g glucose/kg 
body weight intraperitoneally and blood collected every 30 minutes for 90 minutes to measure glucose 
levels. Mice will then be euthanized (CO2 inhalation) to collect brain, adrenal glands, liver, spleen, 
mesenteric lymph nodes and adipose tissue for histology, biochemistry and immune cells harvest.  
The same experimental approach will be used for Specific Aim 2, except the lard diet will be replaced 
by the fish oil based western diet. 
Specific Aim Western Diet type                     Treatment 
1 (n = 40) Lard                        Plus Glucocorticoid No Glucocorticoid 






The goal of this experiment is to mimic the metabolic syndrome that is induced in the 
pediatric population treated for acute lymphoblastic leukemia. No restriction or dietary 
advice is currently given to these patients. We are interested in the kinetics of the onset 
of the syndrome and also what role the immune system plays is setting up the 
environment for the disorder.  
 
The C57BL/6 diet induced obesity (dio) mouse model has been used previously to look 
at the effect of excess weight on various organ systems. As we are interested in the 
interaction between the immune system and other organs and what role it plays in the 
onset of metabolic phenotype, we cannot use isolated cell lines or model organisms such 
as yeast. Additionally, many reagents have been developed for the use of mouse tissues, 
especially antibodies that will be used to identify immune populations. 
 
There will be 10 mice per group for each time point. This number should be sufficient to 





C. Rationale for Involving Animals and the Appropriateness of Species and 
Number Used. 
 
Indicate (here) briefly the short and/or long-term benefits (to humans and/or other 
animals) of this use of animals for research, teaching or demonstration.  In addition, 
state briefly why living animals are required for this study, rather than some alternative 
model. 
 
D.  Do the procedures described in B above, have the potential to inflict more than 
momentary pain or distress (this does not include pain caused by injections or other 








If yes, please address the following:  
I have considered alternatives to procedures that might cause more than momentary or 
slight pain/distress, and I have not found such alternatives.  As such, I have used one or 
more of the following methods and sources to search for such alternatives: (check below 
each method used) 
   Agricola Data Base  Medline Data Base         CAB Abstracts 
   TOXLINE  BIOSIS                           Lab. Animal Sci. 
Journal 
   Lab. Animals Journal  Lab Animal                    Animal Welfare Info 
Center 
  ATLA (Alternatives to Laboratory Animal Journal)       Quick Biblio. Series 
Lab Animal Welfare Bibliography (QL55L27311988)  "Benchmarks" 
 "Alternatives to Animal Use in Research, Testing and Education" 
 Current Contents 
 CARL 
 Direct contact with colleagues (if selected, you MUST document this below) 
What is the length of time that the literature search covers 
III. Animal Use 
A. List all animal species to be used (example below). 
Species Number1                     Age2    Sex             Weight2           (Bldg./Rm#) 
Hooded Wistar rats  45 2 months male 250-350 gm 
Psychology 
Bld./422I 




        1Individuals using ectotherms need to only approximate numbers. 





Is any species threatened or endangered?                                 Yes           No  X 
B.  Source of animals 
X  Commercial vendor (Source: Jackson Labs) Female mice will be purchased to breed 
with male mice available on the UM campus 
X  Bred at The University of Memphis  
 Captured from wild  
 Transferred from another study (IACUC) Protocol Number                                                       
 Donated (Source)                                                                                                                      
 Tennessee Wildlife Resources Agency 
 Purchased and supplied by TMGC  
Is the supplier a USDA approved source?                                Yes           No   
If not, explain why:  
 Animals are already in residence at U of M 
C. Will surgery be conducted on animals?                           Yes           No   
If yes, complete this section: 
   Non Recovery Surgery  Recovery Surgery 
    Multiple Survival Surgery (if the latter is checked, complete section F) 
Surgeon(s) (Name/Job/Title/Academic Rank    Location of Surgery (Bldg. & Room #) 
D.  Will Anesthetic(s), Analgesic(s), or  
 Tranquilizing agents be administered?                                     Yes  X         No                 
If yes, complete this section (example below). 





50 mg/kg   i.p. Mr. Smith/Research Technician/B.Sc. 
C57BL/6 mice Isoflurane     2-4% Inhalation Marie van der Merwe/ Assistant 
Professor 
Simone Godwin/Masters Student 





E. Will euthanasia be carried out?                                                Yes  X         No                    
If yes, complete this section (example below).  






mg/kg   
i.p. Mr. Smith/Research 
Technician/B.Sc. 
C57BL/6 mice CO2 3L/min Inhalatio
n 
Marie van der Merwe/ Assistant 
Professor 
Simone Godwin/Masters Student 
LeeAnnaBeech/Masters Student 
 
If no, describe disposition of animal(s) at conclusion of this study in box below. 
 
F. Will special housing, conditioning, diets or other conditions  
 be required?                                                                                              Yes  X         No  
 
If yes, please explain in box below.              
 
G. Will animals be removed from the U of M campus at any time?  Yes           No  X 
If yes, please indicate to where and for how long in box below. 
 
G. If they are to be housed for more than 24 hours outside approved facilities at U of 
M, provide a scientific justification in box below 
 
 
Mice will be on special high fat (either lard/fish oil) diets in addition to receiving daily 





IV. Toxic and Hazardous Substances 
A. Check off any of the following below that will be used in these experiments? 
 Infectious agents (Fill out a, b) 
 Radioisotopes (Fill out a, b, e) 
 Toxic chemicals or carcinogens (Fill out a, b) 
 Recombinant DNA (Fill out a) 
 Experimental drugs (Fill out a) 
 Malignant cells or hybridomas (Fill out a, c) 
 Adjuvants (Fill out a) 
 Controlled substances (Fill out a, d, e) 
For each checked off category, answer the questions indicated below: 
a. Identify the substance(s) and completely describe their use, including how will be 
injected or given to the animal(s):  
b. Describe all procedures necessary for personnel and animal safety including 
 biohazardous waste, carcass disposal and cage decontamination: 
c. If transplantable tumors or hybridoma cells are to be injected into the 
animals, have the tissues/cells been tested for inadvertent contamination by viruses or 
mycoplasma?                                               Yes           No   
 
d. In the box below, provide a complete list of these substances, and if their use is not 
explicitly explained in the materials already provided, explain their use and role in the 
research. 
Provide DEA license # covering the use of these substances:   
To whom (or what entity) is the license issued?   
e. Provide Radioisotope License Number:   
     To whom is the license issued?   
 
V.  Categories of Animal Experimentation Based Upon Level of Manipulation and 




X A. Animals will be involved in teaching, research, experiments or tests involving 
 no pain, distress, or use of pain-relieving drugs. 
X B.  Animals  will be subject to mild stress only (e.g., food or water deprivation of 
less than 24 hours for use in behavioral studies such as operant 
conditioning; physical restraint for less than 30 minutes), and will not be 
subject to surgery, painful stimuli, or any of the other conditions described 
below. Procedures described in this protocol have the potential to inflict no 
more than momentary or slight pain or distress on the animal(s)----that is, 
no pain in excess of that caused by injections or other minor procedures 
such as blood sampling.  
X C. Animals will have minor procedures performed, blood sampling, etc. while 
anesthetized.  
X D. Live animals will be humanely killed without any treatments, manipulations, 
etc. but will be used to obtain tissue, cells, sera, etc.  
 E. Live animals will have significant manipulations, surgery, etc. performed 
while anesthetized. The animals will be humanely killed at experiment 
termination without regaining consciousness.  
 F. Live animals will receive a painful stimulus of short duration without 
anesthesia (behavior experiments with flight or avoidance reactions--e.g., 
shock/reward) resulting in a short-term traumatic response. Other examples 
in this category are, blood sampling, injections of adjuvants, or drugs, etc.  
 G. Live animals will have significant manipulations performed, such as 
surgery, while anesthetized and allowed to recover. Such procedures cause 
post-anesthetic pain/discomfort resulting from the experiment protocol (e.g., 
chronic catheters. surgical wounds, implants) which cause a minimum of 
pain and/or distress. Also included are mild toxic drugs or chemicals, tumor 
implants (including hybridomas). tethered animals, short-termed physically 
restrained animals (up to 1 hour), mother/infant separations.  
 H. Live animals will have significant manipulations or severe discomfort, etc. 
without benefit of anesthesia, analgesics or tranquilizers. Examples to be 
included in this category are: toxicity testing, radiation sickness, irritants, 
burns, trauma, biologic toxins, virulence challenge, prolonged: restrictions 
of food or water intake, cold exposure, physical restraint or drug addiction. 
All use of paralytic agents (curare-like drugs) must be included in this 
category.  Describe any abnormal environmental conditions that may be 
imposed.  Describe and justify the use of any physical restrain devices 





VI. Justifications for Category G Studies and Deviations from Standard 
Techniques 
Describe in the box below any steps to be taken to monitor potential or overt pain and/or 
distress during the course of this study and how such pain or distress will be alleviated. 
Be as detailed as necessary to justify your procedure.   
 
VII.  Certifications 
(By submitting this protocol, I am acknowledging that I comply with the 
certifications included in Section VII.)  (check one) 
X Animal Use for Research. I certify that the above statements are true and the protocol 
stands as the original or is essentially the same as found in the grant application or 
program/project. The IACUC will be notified of any changes in the proposed 
project, or personnel, relative to this application, prior to proceeding with any 
animal experimentation. I will not purchase animals nor proceed with animal 
experimentation until approval by the IACUC is granted. 
 Animal Use for Teaching/Demonstration. I certify that the information in this 
application is essentially the same as contained in the course outline and a copy of 
the laboratory exercises using animals is on file in the IACUC office. The IACUC 
will be notified of any changes in the proposed project, or personnel, relative to 
this application, prior to proceeding with any animal experimentation. I will not 
proceed with animal experimentation until approval by the IACUC is granted.  
Estimate the cost of maintaining animals used in this protocol based on current per diem 
charge at University of Memphis. 
 
Please specify cost per unit of time:  
 
Specify anticipated total costs for project duration:   
As supervisor of this project it is required that you inform your department chair 
concerning any animal per diem costs related to this project that are to be paid by 
the department.  
 
 
    $ 24/day  (24c/cage/day) 




By submitting this protocol, the Principal Investigator/Course Director indicates 
that the following have been considered: 
1. Alternatives to use of animals. 
2. Reduction of pain and stress in animals to the lowest level possible.  
3. The proper needs of the animals with respect to housing and care.  
4. The lowest number of animals used that will give the appropriate experimental results.  
5. Use of the most primitive species that will give the appropriate experimental results.  
6.  Proper training of all personnel in the care and handling of the species used and in 
the procedures called for in this protocol before beginning the 
experiment/teaching or demonstration.  
7. That this protocol is not an unnecessary repeat of results already in the literature or in 
the case of teaching/demonstrations, results that can be demonstrated using 
models or video material.  
 




Date   
Federal Law requires that members of the IACUC be given adequate time to read and 
review protocols including any changes or revisions in them. 
The University of Memphis IACUC evaluates protocols on a continuous basis.  Any 
protocols or modifications or renewals to any protocols to be considered at this time 
must be received by the Animal Care Facility no later than the end of the second week of 
the previous month. 
Incomplete protocols will be returned to the principal investigator. We will not accept a 
FAXed protocol, renewal form or changes to a protocol. 
E-mail the completed protocol to Dr. Guy Mittleman (Dept. Psychology): 
mailto:<g.mittleman@mail.psyc.memphis.edu>?subject=RE:  IACUC Application 
January, 2008 
 
    Marie van der Merwe 
    mvndrmrw@memphis.edu 
    7/21/14 
